According to findings appearing in the April 2009 print issue of the Clinical Journal of the American Society of Nephrology (CJASN), Rituximab can prove its usefulness in treating patients with membranous nephropathy, a kidney disorder.
It is important to note that present treatment options for treating this ailment are calcineurin inhibitors, steroids, and chemotherapeutic agents, all of which have some side effects.
Andrew Bomback, MD (University of North Carolina Kidney Center), and his colleagues after conducting the first systematic review of rituximab use in patients with membranous nephropathy evaluated the effect of rituximab when it comes to curing patients struggling against nephropathy.
From News-Medical.Net:
To investigate rituximab's potential, Andrew Bomback, MD (University of North Carolina Kidney Center), and his colleagues conducted the first systematic review of rituximab use in patients with membranous nephropathy. They collected and analyzed all of the data available on rituximab therapy in this patient population. They found 21 articles to date, all of which were either case reports or case series without controls, meaning that patients taking rituximab were studied for a certain length of time but were not compared with patients not taking the drug.
Dr. Bomback remarked further that further studies are needed for finding the true and complete value of this drug and the usage must be done in research setting till then.
Posts
No comments:
Post a Comment